Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.

BMC Med · 2024 · PMC10877779 · PMID 38378570

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In flow cytometry, we observed a noticeable increase in the percentage of CD3 + /CD8 + in the RCP group (though it did not reach statistical significance), but it remained relatively unchanged in the BBIBP-CorV group (Fig. 3 C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.